Kineta To Host KOL Event To Review New Data From VISTA-101 Clinical Trial Of KVA12123 In Patients With Advanced Solid Tumors On December 5, 2023
Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will host a virtual KOL